1. Home
  2. ETO vs ALT Comparison

ETO vs ALT Comparison

Compare ETO & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eaton Vance Tax-Advantage Global Dividend Opp

ETO

Eaton Vance Tax-Advantage Global Dividend Opp

HOLD

Current Price

$31.93

Market Cap

493.0M

Sector

Finance

ML Signal

HOLD

Logo Altimmune Inc.

ALT

Altimmune Inc.

HOLD

Current Price

$3.01

Market Cap

421.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ETO
ALT
Founded
N/A
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
493.0M
421.5M
IPO Year
2004
2005

Fundamental Metrics

Financial Performance
Metric
ETO
ALT
Price
$31.93
$3.01
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$17.67
AVG Volume (30 Days)
29.5K
4.1M
Earning Date
01-01-0001
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
25.37
EPS
N/A
N/A
Revenue
N/A
$41,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
105.00
52 Week Low
$25.68
$2.56
52 Week High
$31.89
$6.44

Technical Indicators

Market Signals
Indicator
ETO
ALT
Relative Strength Index (RSI) 67.71 52.09
Support Level $29.52 $2.65
Resistance Level N/A $3.09
Average True Range (ATR) 0.52 0.17
MACD 0.16 0.01
Stochastic Oscillator 100.00 43.75

Price Performance

Historical Comparison
ETO
ALT

About ETO Eaton Vance Tax-Advantage Global Dividend Opp

Eaton Vance Tax-advtgd Global Divid Oppo is a diversified, closed-end management investment company. Its investment objective is to provide a high level of after-tax total return consisting of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. The portfolio of investments consists of capital markets, chemicals, diversified, beverages, banks, electric utilities, oil, gas, and consumable fuels, personal products, and other areas.

About ALT Altimmune Inc.

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: